Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea.

[3][4][5] It is a dual orexin OX1 and OX2 receptor antagonist (DORA).

[1] As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea.

[1][2] It was designed to have a short half-life and duration in order to reduce next-day side effects like somnolence.

[5] This drug article relating to the nervous system is a stub.